Cyclosporine Market Report 2026

The cyclosporine market size has grown rapidly in recent years. It will grow from $2.98 billion in 2025 to $3.37 billion in 2026 at a compound annual growth rate (CAGR) of 13%. The growth in the historic period can be attributed to growth in organ transplant procedures, established efficacy in immune suppression, increasing autoimmune disease prevalence, early regulatory approvals, expansion of hospital-based immunotherapy use.

The cyclosporine market size is expected to see rapid growth in the next few years. It will grow to $5.46 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to rising chronic autoimmune conditions, expanding ophthalmic disease burden, increasing transplant survival rates, wider availability of generics, growing outpatient immunosuppressive therapy use. Major trends in the forecast period include expanding use in autoimmune disease management, growing adoption of ophthalmic cyclosporine formulations, rising demand for long-term immunosuppressive therapies, increased use in organ transplant maintenance regimens, growth of generic cyclosporine products.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the cyclosporine market in the coming years. Autoimmune diseases are conditions in which the immune system erroneously attacks the body’s own cells, leading to inflammation, tissue damage, and chronic illness. The rising occurrence of autoimmune diseases can be linked to genetic predisposition, as advancements in genetic testing have identified more individuals with hereditary risks, making them more vulnerable to these conditions. Cyclosporine works effectively for autoimmune diseases by inhibiting T-cell activation, thereby minimizing harmful immune responses against healthy tissues in disorders such as rheumatoid arthritis, psoriasis, and lupus. For example, in October 2024, a comprehensive review published in Signal Transduction and Targeted Therapy, a journal by Nature, reported that approximately 8.4 million patients worldwide suffer from rheumatoid arthritis, with the total incidence rate increasing by 2-3% annually; using a Markov model approach, the affected population is projected to reach around 13.5-17.4 million by 2040. Consequently, the rising prevalence of autoimmune diseases is fueling the expansion of the cyclosporine market.

Major companies operating in the cyclosporine market are concentrating on securing regulatory approvals to broaden their product offerings and strengthen their market position. Regulatory approvals for cyclosporine confirm its safety and effectiveness, allowing market access while increasing confidence among prescribers and patients. For example, in June 2023, Novaliq GmbH, a Germany-based biopharmaceutical firm, obtained approval from the U.S. FDA for VEVYE (cyclosporine ophthalmic solution) 0.1%, a distinctive water-free ophthalmic medication developed for the treatment of dry eye disease (DED). It is the first and only cyclosporine-based solution for this indication, demonstrating effectiveness within just four weeks. VEVYE utilizes an innovative water-free technology called EyeSol, which enhances cyclosporine’s bioavailability and retention on the ocular surface without relying on preservatives, oils, or surfactants. The solution acts as a calcineurin inhibitor, aiding in the reduction of inflammation associated with dry eye disease.

In July 2024, Lupin Limited, an India-based pharmaceutical company, collaborated with Huons Co. Ltd. to introduce a cyclosporine ophthalmic nanoemulsion in Mexico. This collaboration aims to market the product as an advanced treatment for dry eye syndrome and ocular inflammation, expanding Lupin’s ophthalmology portfolio and improving patient care. Huons Co. Ltd. is a South Korea-based pharmaceutical company focused on the development and commercialization of cyclosporine-based ophthalmic therapies.

Major companies operating in the cyclosporine market are Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd, Sandoz International GmbH, Sun Pharmaceutical Industries Ltd, Apotex Inc., Cipla Ltd, Dr. Reddy's Laboratories Ltd, Lupin Limited, Glenmark Pharmaceuticals Ltd, Taj Pharmaceuticals Limited, Panacea Biotec Ltd, Novaliq GmbH, Simson Pharma Limited, Strides Pharma Science Ltd, AdvaCare Pharma, JoinHub Pharma, Grevis Pharmaceuticals Pvt Ltd, GMT Pharma International, Logos Pharma.

Asia-Pacific was the largest region in the cyclosporine market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the cyclosporine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cyclosporine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the cyclosporine market by increasing the cost of imported active pharmaceutical ingredients, formulation excipients, and ophthalmic-grade raw materials used in immunosuppressive drugs. These impacts have been most pronounced in branded oral and ophthalmic segments, particularly in north america and europe where API sourcing is globally diversified. Asia-pacific manufacturers have faced pricing pressure and supply variability due to trade dependencies. However, tariffs have encouraged domestic API synthesis and local formulation manufacturing, supporting long-term supply stability.

The cyclosporine market research report is one of a series of new reports that provides cyclosporine market statistics, including cyclosporine industry global market size, regional shares, competitors with a cyclosporine market share, detailed cyclosporine market segments, market trends and opportunities, and any further data you may need to thrive in the cyclosporine industry. This cyclosporine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cyclosporine is a medication that suppresses the immune system, mainly used to prevent rejection of organ transplants and to manage certain autoimmune disorders. It functions by blocking T-cell activity through the inhibition of the enzyme calcineurin, which in turn decreases inflammation and immune reactions. Additionally, it is available in eye drop formulations to address ocular conditions like dry eye disease.

The primary uses of cyclosporine include transplant rejection prevention, rheumatoid arthritis, psoriasis, autoimmune myasthenia gravis, dry eye, and other conditions. Transplant rejection prevention involves using cyclosporine to stop the immune system from attacking transplanted organs, such as kidneys, livers, or hearts. It is available in various dosage forms, including capsules, eye drops, liquid solutions, creams, and ointments, and can be administered via oral, topical, or parenteral routes. The drug is supplied through hospital pharmacies, retail pharmacies, and online pharmacies, serving end users such as hospitals, homecare services, specialty centers, and others.

The cyclosporine market consists of sales of injectable cyclosporine, ophthalmic formulations, intravenous solutions, topical formulations, and oral solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.